Omega‐3 fatty acids, cardiovascular risk, and the resolution of inflammation
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Although a high marine food intake is considered cardioprotective, randomized trials of ω‐3 fatty acids initially generated conflicting results in terms of the role of ω‐3 supplementation in cardiovascular prevention. This work demonstrates the results of the 3 most recent clinical trials with ω‐3 fatty acids are put into the context of possible mechanisms mediating their beneficial cardiovascular effects. In particular, the randomized Reduction of Cardiovascular Events with EPA Intervention Trial (REDUCE‐IT) showed that icosapent ethyl, which is the ethyl ester form of the ω‐3 fatty acid eicosapentaenoic acid (EPA), induced a significant reduction of cardiovascular events. Importantly, EPA serves as a substrate for the formation of the specialized proresolving mediator resolvin E1 (RvE1), which stimulates the resolution of inflammation. RvE1 reduces atherosclerosis and intimai hyperplasia by means of its specific receptor ERV1/ChemR23. The decreased levels of proinflammatory and proatherosclerotic leukotrienes by ω‐3 fatty acids may further contribute to a beneficial inflammatory balance. Consequently, the Rv/leukotriene ratio is emerging as a marker of nonresolving vascular inflammation. Recent experimental studies have shown that anti‐inflammatory and proresolving effects of lipid mediators derived from ω‐3 fatty acids inhibit atherosclerosis independently of cholesterol and triglyceride levels. The results of the 3 most recent clinical trials of ω‐3 fatty acid supplementation indicate an importance of the type and dose of ω‐3 supplementation and highlight the need for risk stratification in the patient selection for ω‐3 supplementation for either primary or secondary prevention of cardiovascular disease.—Bäck, M., Hansson, G. K. Omega‐3 fatty acids, cardiovascular risk, and the resolution of inflammation. FASEB J. 33, 1536–1539 (2019). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Progress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010 · cited 1×
“Chronic inflammation is a well-established effector in atherosclerosis and a marker of increased cardiovascular risk (5).”
BackgroundSelf-citationPro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041 · cited 1×
“is maintained by a failure in the resolution of inflammation (7).”
BackgroundResolvins in inflammation: emergence of the pro-resolving superfamily of mediators
Serhan, C. N., & Levy, B. D. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97943 · Cited by 1,344 · cited 2×
“With the activation of specific receptors (13), SPMs actively terminate the inflammatory reactions by means of, for example, removal of dead cells (efferocytosis), increased phagocytosis, and leukocyte egress from the site of inflammation (11, 14).”
BackgroundSerhan, C. N., Clish, C. B., Brannon, J., Colgan, S. P., Chiang, N., & Gronert, K. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.8.1197 · Cited by 1,189
Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698
The role of non-resolving inflammation in atherosclerosis
Kasikara, C., Doran, A. C., Cai, B., & Tabas, I. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97950 · Cited by 266 · cited 3×
“Indeed, a decreased ratio between SPMs and leukotrienes is characteristic of vulnerable atherosclerotic lesions (14)andmaybeusedasabiomarker fora nonresolving inflammation in subjects with subclinical atherosclerosis (18).”
BackgroundLaguna-Fernandez, A., Checa, A., Carracedo, M., Artiach, G., Petri, M. H., Baumgartner, R., Forteza, M. J., Jiang, X., Andonova, T., Walker, M. E., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032801 · Cited by 141 · cited 5×
“lating EPAmetabolite through lipidomic analysis (21).”
BackgroundInfluentialSelf-citationThul, S., Labat, C., Temmar, M., Benetos, A., & Bäck, M. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317694464 · Cited by 81
Self-citation
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Influence of Mediterranean Diet on Human Gut Microbiota
Merra, G., Noce, A., Marrone, G., Cintoni, M., Tarsitano, M. G., Capacci, A., & De Lorenzo, A. (2020) · Nutrients · doi:10.3390/nu13010007 · Cited by 417
Sarcopenia during COVID-19 lockdown restrictions: long-term health effects of short-term muscle loss
Kirwan, R., McCullough, D., Butler, T., Perez de Heredia, F., Davies, I. G., & Stewart, C. (2020) · GeroScience · doi:10.1007/s11357-020-00272-3 · Cited by 324
Oppedisano, F., Macrì, R., Gliozzi, M., Musolino, V., Carresi, C., Maiuolo, J., Bosco, F., Nucera, S., Caterina Zito, M., Guarnieri, L., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8090306 · Cited by 323
Inflammation and nutrition: friend or foe?
Stumpf, F., Keller, B., Gressies, C., & Schuetz, P. (2023) · Nutrients · doi:10.3390/nu15051159 · Cited by 213
Metadata
- Authors
- Bäck, M., & Hansson, G. K.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2019-01-17
- Volume
- 33
- Issue
- 2
- Pages
- 1536-1539
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2911252450
- Cited by
- 104
- References
- 9
- FWCI
- 10.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Omega‐3 fatty acids, cardiovascular risk, and the resolution of inflammation. https://app.cochat.ai/papers/10.1096/fj.201802445r
- The paper
- Bäck, M., & Hansson, G. K. (2019). Omega‐3 fatty acids, cardiovascular risk, and the resolution of inflammation. The FASEB Journal. https://doi.org/10.1096/fj.201802445r
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.